Ex-Taris CEO Tony Kingsley claims tenure as Scholar Rock’s new CEOAfter more than eight years at the helm of US biotech Scholar Rock, Nagesh Mahanthappa is standing down Share XEx-Taris CEO Tony Kingsley claims tenure as Scholar Rock’s new CEOhttps://pharmaphorum.com/news/ex-taris-ceo-tony-kingsley-claims-tenure-as-scholar-rocks-new-ceo/
FDA delays decision on Roche’s SMA drug to review extra dataThe FDA has extended its review of Roche’s spinal muscular atrophy (SMA) drug risdiplam after the pharma submitted Share XFDA delays decision on Roche’s SMA drug to review extra datahttps://pharmaphorum.com/news/fda-delays-decision-on-roches-sma-drug-to-review-extra-data/
FDA lets off Novartis after gene therapy data rowNovartis is off the hook following the FDA’s review of data manipulation in the filing of its hugely Share XFDA lets off Novartis after gene therapy data rowhttps://pharmaphorum.com/news/fda-lets-off-novartis-after-gene-therapy-data-row/
Novartis closes on EU approval for SMA gene therapy ZolgensmaNovartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in Share XNovartis closes on EU approval for SMA gene therapy Zolgensmahttps://pharmaphorum.com/news/novartis-closes-on-eu-approval-for-sma-gene-therapy-zolgensma/
Novartis publishes long-term data from SMA gene therapyNovartis has produced data demonstrating its Zolgensma gene therapy produces long term benefits in the rare muscle wasting Share XNovartis publishes long-term data from SMA gene therapyhttps://pharmaphorum.com/news/novartis-publishes-long-term-data-from-sma-gene-therapy/
Novartis pulls rival to Roche’s risdiplam in SMA, says market limitedWhile Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market Share XNovartis pulls rival to Roche’s risdiplam in SMA, says market limitedhttps://pharmaphorum.com/news/novartis-pulls-rival-to-roches-risdiplam-in-sma-says-market-limited/
FDA cues up May verdict for Roche’s SMA challenger risdiplamThe FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision Share XFDA cues up May verdict for Roche’s SMA challenger risdiplamhttps://pharmaphorum.com/news/fda-cues-up-may-verdict-for-roches-sma-challenger-risdiplam/
Zolgensma hits the ground running, says NovartisNovartis’ Zolgensma gene therapy for spinal muscular atrophy is the most expensive drug in the world, but that Share XZolgensma hits the ground running, says Novartishttps://pharmaphorum.com/news/zolgensma-hits-the-ground-running-says-novartis/
AveXis rules out EU compassionate use of SMA gene therapy, says Biogen option is availableNovartis’ AveXis unit has given its reasons for refusing to supply its spinal muscular atrophy gene therapy Zolgensma Share XAveXis rules out EU compassionate use of SMA gene therapy, says Biogen option is availablehttps://pharmaphorum.com/news/avexis-rules-out-eu-compassionate-use-of-sma-gene-therapy-zolgensma/
